Eric J. Topol, MD

Nasal administration of such molecules protected mice from collagen-induced arthritis [135] erectile dysfunction after prostatectomy buy cheap aczone 60 mg on-line. The tolerance-induced protection was associated with reduced levels of antigen-specific antibodies and Th1 and Th17 responses [135] and could be induced after oral therapy with an edible form of this molecule expressed in a plant [136] (Chapter 21: Plant-based Mucosal Immunotherapy) erectile dysfunction case study buy cheap aczone on-line. The ability to disassociate their toxicity and their modulatory effects led to the development of safer derivatives that could be incorporated in future human vaccines erectile dysfunction under 35 30 mg aczone purchase fast delivery. The fact that toxin subunits or toxin derivatives expressed in plant impotence from diabetes aczone 60 mg generic, or live recombinant microbial vector can modulate immune responses and promote mucosal immunity will certainly have a significant impact on the development of future prophylactic and therapeutic vaccines erectile dysfunction vyvanse generic aczone 90 mg mastercard. Stability of vaccines throughout the cold chain and the need for trained health care professionals and needles are major points to consider for production and distribution of vaccines. The extensive stability at room temperature of vaccines expressed in rice and the ease of oral administration of rice power will likely boost the development of plant-based vaccines containing different toxin subunits or toxin derivatives as adjuvant. While toxin adjuvants were initially used to increase immune responses, reports that formulations containing toxin subunits or enzymatically inactive derivatives can suppress unwanted immune responses such as autoimmune or allergic responses [137] will likely increase their use for applications unrelated to protection against infectious pathogens. However, a knowledge gap still remains to be filled about host cell response to toxin subunits and derivatives. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. Fucosylation and protein [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] glycosylation create functional receptors for cholera toxin. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity. Inactivation of the Escherichia coli heat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Direct effects on antigenpresenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7. Intranasal immunogenicity and adjuvanticity of sitedirected mutant derivatives of cholera toxin. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection. Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Induction of hepatitis C virusspecific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon. Neutrophils negatively regulate induction of mucosal IgA responses after sublingual immunization. Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. The adenylate cyclase toxin of Bacillus anthracis is a potent promoter of T(H) 17 cell development. Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. Oral MucoRice expressing doublemutant cholera toxin A and B subunits induces toxinspecific neutralising immunity. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. Cholera toxin and Escherichia coli heatlabile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. Feeding transgenic plants that express a tolerogenic fusion protein effectively protects against arthritis. Escherichia coli heat-labile detoxified enterotoxin modulates dendritic cell function and attenuates allergic airway inflammation. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. Gut T cell receptor-gammadelta(1) intraepithelial lymphocytes are activated selectively by cholera toxin to break oral tolerance in mice. Therapeutic potential of cholera toxin B subunit for the treatment of inflammatory diseases of the mucosa. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. These cells are continuously exposed to dietary components and pathogenic and commensal microorganisms, and together, these provide a selective barrier against harmful materials and microorganisms and permit beneficial interactions to take place. Dietary components such as vitamins and metabolites produced by commensal bacteria are essential for the development and maintenance of the immune system [1]. Indeed, poor or excess nutrient intake has been shown to increase the risk of infection and susceptibility to inflammatory or allergic diseases. Therefore, understanding the immunological functions of dietary components and metabolites will provide useful insights for the development of effective mucosal vaccines. In this article, we focus on the immunological relevance of how nutrients influence the regulation of the host immune system and discuss how this knowledge can be applied to develop improved and effective mucosal vaccines. Vitamins are classified as either hydrophilic (vitamin B complex, vitamin C) or hydrophobic (vitamins A, D, E, and K). Since mammals, including humans, are unable to synthesize most vitamins [1], they must be obtained from the diet or be produced by commensal bacteria in the gut [2]. Vitamin A Vitamin A is essential for the maintenance of physiological functions such as cell differentiation and reproduction. Vitamin A-deficient mice have been shown to be highly susceptible to infection by Citrobacter rodentium and Escherichia coli and to be at high risk of developing immune diseases [3,4]. Similarly, in children, vitamin A deficiency is associated with a high susceptibility to infection by the microorganisms that cause measles, diarrhea, and respiratory diseases. Vitamin A is obtained from the diet as alltrans-retinyl esters and -carotene, which are metabolized to retinol [7]. Retinol is then metabolized to retinoic acid by alcohol dehydrogenase and retinal dehydrogenase. These immunological functions of retinoic acid underlie a new type of vaccine strategy. Retinoic acid promotes IgA class-switching and controls positively and negatively the differentiation of naive T cells into regulatory T cells (Tregs) and T helper 17 (Th17) cells, respec¨ tively. Several of the vitamin B complex vitamins play roles in human energy metabolism systems. Although it is well known that vitamin B1 deficiency causes beriberi and WernickeÀ Korsakoff syndrome, it can also affect the efficacy of oral vaccines. For example, mice fed a vitamin B1-deficient diet during oral immunization had decreased levels of antigen-specific IgA in their feces [18]. Since vitamin B3 deficiency causes pellagra, which is characterized by diarrhea and inflammation of the intestine and skin [19], vitamin B3 likely has immunological functions. Vitamin B9 Vitamin B9 is essential for nucleotide and protein synthesis [22]; it also plays an important role in the regulation of the immune system by maintaining the survival of Tregs. In the absence of vitamin B9, Tregs differentiate from naive T cells but do not survive, owing to ¨ decreased expression of antiapoptotic molecules such as Bcl-2 [24]. Indeed, mice fed a vitamin B9-deficient diet have decreased numbers of Tregs in the intestine and increased susceptibility to intestinal inflammation [25]. It is reported that patients with inflammatory bowel disease have low serum levels of vitamin D, and that vitamin D supplementation decreases the inflammatory symptoms in these patients [28]. It is well known that excessive amounts of lipid in the diet leads to the development of inflammation [30]. In addition to the quantity of dietary lipids, the composition of dietary lipids is also an important factor in the regulation of host immunity and inflammation. In general, dietary lipids are composed of long-chain saturated fatty acids and mono- or polyunsaturated fatty acids. Mammals are unable to synthesize omega-3 and omega-6 polyunsaturated fatty acids; therefore, these are referred to as essential fatty acids. To examine the effects of the fatty acid composition of dietary lipids on host immunity, mice were fed a diet containing different types of dietary lipids. We found that allergic responses in the intestine were ameliorated when mice were fed a diet containing linseed oil, which contains high concentrations of -linolenic acid, an omega-3 polyunsaturated fatty acid [31]. Vitamin D Vitamin D is an essential factor for calcium homeostasis and cell differentiation and growth [26]. We also found that the level of intestinal IgA was different depending on the fatty acid composition of dietary lipids [32]. For instance, mice fed a diet containing palm oil had a higher level of intestinal IgA compared with mice fed a diet containing soybean oil. Palm oil and palmitic acid are reported to enhance antigen-specific intestinal IgA responses induced by oral vaccination [32]. This suggests that the high level of palmitic acid in palm oil both directly and indirectly stimulates IgA production and therefore that palmitic acid is a potential mucosal adjuvant. Crosstalk between commensal bacteria and the host immune system has been shown to be important for the development and maintenance of host immune responses, including the production of intestinal IgA [34]. Probiotics are live microorganisms that confer a health benefit to the host, such as modulation of the immune system and suppression of the development of intestinal inflammation and metabolic disorders [37,38]. Probiotics have various effects on immune cells, such as cytokine and IgA production. Commensal bacteria, such as Lactobacillus species, produce short-chain fatty acids such as acetate, propionate, and butyrate from dietary fiber that act as effector molecules.

Multiepitope Protein Antigens Several groups have used bioinformatics to link epitopes of fimbrial adhesins together with epitopes of toxins and/or other surface exposed proteins for use as parenteral vaccines [59 erectile dysfunction psychological treatment purchase aczone 90 mg,68] erectile dysfunction trimix aczone 90 mg purchase without prescription. A remaining challenge for this concept and other subunit vaccine candidates that are immunogenic when given parenterally to mice is to establish a suitable administration route in humans erectile dysfunction daily medication purchase aczone 30 mg fast delivery, resulting in potent local secretory immune response in the small intestine erectile dysfunction caused by spinal stenosis order aczone without prescription. Chitosan has been tested in humans for oral drug delivery but not specifically as an oral adjuvant [74] impotence jokes buy discount aczone 90 mg on line. The mutation inactivates a trypsin-sensitive site in the A subunit that separates the A1 from the A2 unit, effectively stopping the nicking of the protein. The second mutation, L211A, is located at a putative pepsin sensitive site in the A2 domain. However, since this method is very laborious and time consuming, we have searched for alternative approaches to determine responses that may reflect mucosal immune responses locally in the gut. Determination of mucosal immune responses in saliva (to be published) or in serum [42] has been less sensitive, particularly in individuals V. Also the route of administration varies, from oral to parenteral to skin administration. In the youngest children, a full adult dose was associated with an increased frequency of vomiting; however, a quarter of a full dose of vaccine was safe and immunogenic [85]. Despite promising preliminary results in a small phase 2 trial, in which an overall protection rate of 75% against all-cause moderate to severe diarrhea was recorded in European travelers to Guatemala or Mexico [82], the vaccine did not meet its primary objectives in a subsequent phase 2 trial in India [83] or in a larger phase 3 trial [84] in European travelers to Guatemala or Mexico. Immunogenicity data indicated that there was a robust vaccine take; 84%À90% of the participants seroconverted with IgG and IgA antibodies V. All these colonization facors have been shown to be protective in animal studies [8]. Furthermore, the avidity of the immune responses was also higher after the late booster than after the two initial vaccinations [89]. Based on these promising results a large phase 1À2 trial (495 subjects) was initiated in descending age groups in Bangladesh. Responses in the Bangladeshi adults were higher and more frequent than responses previously recorded in adult Swedes. Promising new noncanonical antigens have been proposed on the basis of new knowledge acquired through whole genome sequencing and reversed vaccinology [59,93,94]. Vaccine Candidates in Clinical Development the tip adhesin strategy pioneered by Savarino et al. Production is taking place on a commercial scale, and the vaccine has been shown to be highly immunogenic both in Western adults and in adults and young children in the developing world. The efficacy of the vaccine in adult European travelers to Africa is being tested in a phase 2b trial. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Experimental enterotoxin-induced Escherichia coli diarrhea and protection induced by previous infection with bacteria of the same adhesin or enterotoxin type. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. Prophylactic efficacy of hyperimmune bovine colostral antiadhesin antibodies against enterotoxigenic Escherichia coli diarrhea: a randomized, double-blind, placebo-controlled, phase 1 trial. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Lack of prophylactic efficacy of an enteric-coated bovine hyperimmune milk product against enterotoxigenic Escherichia coli challenge administered during a standard meal. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Evolutionary and functional relationships of colonization factor antigen I and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli. Evolution of the chaperone/ ¨ usher assembly pathway: fimbrial classification goes greek. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Essential structure for full enterotoxigenic activity of heat-stable enterotoxin produced by enterotoxigenic Escherichia coli. Molecular structure of the toxin domain of heat-stable enterotoxin produced by a pathogenic strain of Escherichia coli. A putative binding site for a binding protein on rat intestinal epithelial cell membranes. Development of an enterotoxigenic Escherichia coli vaccine based on the heat-stable toxin. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] V. Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] enterotoxigenic Escherichia coli. Role in proinflammatory response of YghJ, a secreted metalloprotease from neonatal septicemic Escherichia coli. Identification of a two-partner secretion locus of enterotoxigenic Escherichia coli. Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins. EatA, an immunogenic protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pyloriÀinfected adults. Current progress in developing subunit vaccines against enterotoxigenic Escherichia coli-associated diarrhea. Towards rational design of a toxoid vaccine against the heat-stable toxin of Escherichia coli. Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin. Design and characterization of a chimeric multiepitope construct containing CfaB, heat-stable toxoid, CssA, [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] V. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6À17 months of age: dosing studies in different age groups. Randomised, doubleblind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. Human experimental challenge with enterotoxigenic Escherichia coli elicits immune responses to canonical and novel antigens relevant to vaccine development. SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains. Most colonized individuals develop marginal inflammation, remaining largely asymptomatic [10]. Barry Marshall and Robert Warren were awarded the Nobel Prize in Physiology and Medicine in 2005 for the discovery of this association [11]. Indeed, several vaccine trials have successfully compensated for this deficit by inducing substantial H. Surprisingly, though, the vaccines failed to confer complete protection against infection [16,17]. In this article, we review recent findings that provide an astounding explanation for the failure of past vaccination attempts. We also illuminate scenarios through which future approaches could lead to better results, also taking into account the possible risks of vaccination. Pathogenic bacteria rely on a large repertoire of tools to suppress immune activation [18]. Besides the exhibition of structural features, such as antigenic mimicry of self-epitopes, they pursue direct interference with immune activation pathways. The result of such failure may, for example, involve an ineffective generation of pathogen-specific immune cells, an unfavorable balance of effector versus regulatory cells, and a failure in generating specific antibodies. However, by applying appropriate vaccination protocols, the deficiency of immune activation could be overcome [19], thus in principle mounting robust protection lines. In fact, successful rational vaccine design strategies have been developed against numerous pathogens through assembling efficacious antigen cocktails in combination with highly potent adjuvants [20]. In this way, appropriate branches of the immune system could be activated, directing immunity toward desired organ sites [21]. Despite great success in preventing various pathogenic infections [22], surprisingly, this strategy appears to fail for H. A combination of two antibiotics is usually given together with a proton pump inhibitor [23]. Further problems associated with antibiotic treatment are linked to low patient compliance, the occurrence of reinfections, and the uncertainty about whether treatment is indicated for asymptomatic patients [25]. In this light, a vaccine, whether prophylactic or therapeutic, would obviously be highly desirable. It would theoretically solve the problems associated with current antibiotic treatment and constitute a milestone for the prevention of peptic ulcer and gastric cancer. Much effort has therefore been invested in developing vaccines in preclinical and clinical settings, but so far, none of them have provided more than scarce protection [15,25À27]. Even in mouse studies, vaccination approaches have mostly achieved only partial reduction of pathogen colonization rather than sterile immunity [28À31]. Thus, failure to achieve sterile immunity could increase the risk of associated gastric cancer [32À34]. Moreover, boosting T helper responses might diminish the immuneregulatory effects associated with H. Owing to the innumerable invaginations, referred to as glands and crypts, as well as the intestinal villi, the gastrointestinal tract displays the largest of these mucosal surfaces. As the digestive channel for passing the essentially nonsterile cargo, the gastrointestinal tract has adapted to keep potentially harmful microorganisms at bay while tolerating colonization by commensal microbes. However, pathogenic bacteria of the mucosa are often equipped with an array of virulence factors capable of disturbing the existing equilibrium and penetrating the mucosal barrier [39]. Accordingly, propagation in the lumen does not provoke substantial responses, while epithelial cell attachment or even cell and tissue invasion induces progressively greater responses, potentially culminating in sepsis, typically associated with an overwhelming inflammatory burst. In a naive situation, these ¨ defense mechanisms will act in the absence of adaptive immunity, relying solely on the action of the immediately available and autonomous surveillance and defense systems of the epithelium [40]. This can, for example, involve the release of antimicrobial molecules and the mobilization of phagocytic and innate epithelial cells to the site of infection. Therefore a correct barrier function of the mucosal surfaces requires tight coordination among many different cell types. Because the epithelial lining of the gastrointestinal tract is permanently exposed to microorganisms, to maintain its integrity it V. Stem cells differentiate into different, specialized epithelial subtypes with distinct cellular functions, such as nutrient absorption and the production and secretion of mucus, hormones, or acid [38,42]. Remarkably, the role of epithelial cells in the defense against mucosal pathogens goes far beyond physical containment. Together with the hematopoietic immune surveillance, epithelial cells are key players in the maintenance and homeostasis of the barrier function. Their location at the border between the external environment and the underlying immune cells allows the epithelial compartment to act as a coordinating hub of mucosal immunity [37]. Epithelial cells display both intracellular and extracellular innate pattern recognition receptors to detect the presence of microbes [37,38,43]. Epithelial sensing of potentially harmful microorganisms triggers the first wave of the innate immune responses, leading to the secretion of chemotactic cytokines that recruit professional immune cells to the site of infection (Chapter 6: Innate Immunity at Mucosal Surfaces). Immune effector function and microbial killing are often associated with "professional" immune cells. However, the epithelium also participates actively in the antimicrobial defense by secreting bactericidal compounds along with mucins [44]. These small molecules may be produced in millimolar concentrations and are active against Gram-positive and Gram-negative bacteria [45]. They kill or inactivate bacteria by inducing leakage of cytoplasmic content, binding to intracellular targets and/or delocalization of membrane proteins [45À47]. This powerful way of clearance- fast, specific to bacteria, and cost-effective in energetic terms-is widespread in both V.

Fertility control in the bitch by active immunization with porcine zonae pellucidae: use of different adjuvants and patterns of estradiol and progesterone levels in estrous cycles erectile dysfunction remedies 30 mg aczone order amex. Effect of alloimmunization and heteroimmunization with zonae pellucidae on fertility in rabbits erectile dysfunction with age statistics purchase genuine aczone on line. Humoral immune responses in brushtail possums (Trichosurus vulpecula) induced by bacterial ghosts expressing possum zona pellucida 3 protein erectile dysfunction diabetes permanent best order aczone. Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula) what is erectile dysfunction wiki answers aczone 90 mg purchase on line. Supression of testicular function in a male Asian elephant (Elephas maximus) treated with gonadotropin-releasing hormone vaccines erectile dysfunction psychological causes discount aczone 30 mg without prescription. Fertility control is much less effective than lethal baiting for controlling foxes. The effect of active immunization against inhibin on gonadotropin secretions and follicular dynamics during the estrous cycle in cows. Efficacy for a new live attenuated Salmonella Enteritidis vaccine candidate to reduce internal egg contamination. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. The efforts to combat malaria are challenged by the complexity of Plasmodium parasite life cycle, which gives rise to distinct developmental stages that express variable antigens, as well as other survival strategies of the parasite, including antigenic polymorphism, antigenic diversion, epitope masking, and host immunosuppression [5]. Malaria infection begins with the injection of Plasmodium parasites in the form of sporozoites from the Anopheles mosquito salivary gland into the skin of the human host. Some of the sporozoites travel to the liver through the bloodstream to infect the liver hepatocytes. After exiting the cycle of liver-stage infection, the parasites are released into the bloodstream in the form of merozoites to begin the pathologic blood-stage infection. The merozoites rapidly invade the erythrocytes and differentiate into ring, trophozoite, and schizont stages by digesting the host hemoglobin for nutrient to grow and multiply. The erythrocytic life cycle of human Plasmodium parasites is 48À72 hours, depending on the species. The parasites continue to differentiate in the mosquito midgut to produce sporozoites to repeat their life cycle again. It has recently been getting attention that Plasmodium parasite presence in different organs should be considered in a tissue-specific context [12]. The intestine is lined with epithelial layer that is folded into villi, which consist of an extensive capillary network and lymphatics for the absorption of nutrients (Chapter 3: Mucosal Antigen Sampling Across the Villus Epithelium by Epithelial and Myeloid Cells). Thus there is a possibility that Plasmodium parasites and infection-related events may disrupt the vascular endothelium in the villi and lead to the activation of immune effector cells scattered in the intestinal epithelium and lamina propria, and this may contribute to the dysregulation of gut homeostasis. This article will review the recent evidence that Plasmodium parasites may have an ability to modify the gut environment and vice versa. We will also discuss possible mucosal vaccination strategies against malaria in the light of recent evidence. Impaired intestinal function with increased permeability in gastric and intestinal mucosa and intestinal damage have been noticed in humans with P. The recent mouse study using a severe Plasmodium berghei cerebral malaria model has shown that the shortening of the villi, bleeding in the small intestine, and sequestration of red blood cells to blood vessels are obvious and might be causing dysbiosis [18]. Malaria and invasive intestinal pathogens such as Salmonella [19À24] or helminthes [25,26] are frequently copresent in malaria-endemic regions, increasing the disease severity [27,28]. It has been shown that an increase in gut mastocytosis during malaria infection may cause increases in ileal and plasma histamine levels and/or cytokine alterations such as interleukin 10, which might be directly associated with increased gut permeability to invasive bacterial infections [24,27,28]. The release of toxic heme due to malaria-induced hemolysis may also cause release of immature neutrophils into circulation that lack reactive oxygen species activity [21,29], although neutrophils are initially fully competent against systemic infection with Plasmodium [30]. Growing evidence indicates the important effects of a "healthy" gut microbiota against several diseases, including malaria [31À33] (Chapter 9: Influence of Commensal Microbiota and Metabolite for Mucosal Immunit). A significant association between the microbiota composition before the malaria season and the risk of P. Microbiota of people with a low risk of malaria contained a significantly higher proportion of Bifidobacterium, Streptococcus, Escherichia, and Lactobacillales [33], suggesting the beneficial effects of these microbes in the gut against malaria. The following mouse study further supported the hypothesis of the role of microbiota on malaria susceptibility by using genetically similar mice from different vendors with different gut microbiomes [32]. Hence it was concluded that the gut microbiome influences the parasite burden and severity of several mouse Plasmodium infections. To directly evaluate the role of Lactobacillus and Bifidobacterium in resistance to severe malaria, the malariasusceptible mice were treated with laboratorycultured yogurt supplemented with these probiotics, and a reducing effect on parasitemia was found [32]. However, the mechanism of microbiota regulation of the host immunity against malaria infection is not fully understood. Parasite sequestration, inflammation, and resultant bleeding due to malaria infection may cause major changes in the gut microbiota composition. For example, the increase in gut mastocytosis during malaria infection may cause increase in ileal and plasma histamine levels and/or cytokine alterations. In addition, the release of toxic heme due to malaria-induced hemolysis may cause immature neutrophil release into circulation, causing exhausted immature neutrophils deficient in killing invasive Salmonella. These changes may lead to dysbiosis and promote the invasion of other intestinal pathogens. On the other hand, gut microbiota may contribute to malaria susceptibility, directly or indirectly. The specific antibodies to some gut pathobionts and/or their metabolites may cross-react with sporozoites and therefore impair transmission of the parasite from mosquitoes to mammalian host. It is possible that the alteration of gut microbiota composition may be controlling the microbial metabolite productions, thus directly or indirectly influencing host immunity. Therefore these possible microbial metabolites need to be further investigated in response to malaria infection. In addition, the low-risk population in Malawi had a substantial proportion of Escherichia in the stool that might be contributing to the protection, although the expression of -gal was not examined in that study [33]. Therefore there is a great potential to use -gal-producing gut bacteria as probiotics to protect from malaria infection. Mucosal vaccines have several advantages, such as the capability of inducing protective immunity locally and systemically with lower cost (less purity is needed, owing to mucosal administration), needle-free delivery, and thus easy mass immunization benefits, especially during pandemics [41]. Moreover, mucosal immunizations have a potential to induce good immunogenicity, owing to having the ability to target larger surface areas with higher vascularity and easy accessibility to lymphoid tissues. Developing vaccines against malaria has been a great challenge, and a systemic subunit protein vaccination strategies has mainly been used [42À44]. The strain-specificity and the polymorphisms of antigens, the short duration of antibodies, and lack of good adjuvants to improve immunogenicity are a few drawbacks of the current strategy of malaria vaccine development. Therefore several strategies, including mucosal immunizations, have been tried, although with questions as to whether this type of immunization is likely to be beneficial against a parasite with a systemic life in erythrocytes, not invading mucosa at all. Later studies have improved the production of Plasmodium antigens in plants [52À56], bacterial outer membrane vesicles [57], or wheat-germ free system [58] to be used for mucosal vaccination against malaria. Another approach was the intranasal or oral immunization with live attenuated Salmonella expressing Plasmodium antigens [59À61], which showed promising results in mice (Table 49. The key question with mucosal immunization against several pathogens, including malaria, is why and how the mucosal vaccination is successful. These accumulated data provide a new platform for the development of suitable antigens as well as adjuvant formulations targeting mucosal surfaces [62,63]. The chapter has also summarized malaria vaccine trials to date that have used mucosal route of immunization. However, it should be kept in mind that many pathogens, including bacteria, viruses, and parasites, are found in resourcelimited settings with no clean water and malnutrition where the mucosal surfaces are more exposed to dangerous pathogens and may have more disruption of mucosal barriers [64]. Therefore there is a great need to address the interaction between pathogens and host mucosal immunity to develop mucosal vaccines against malaria with consideration of other coinfections and conditions in the endemic settings. Acknowledgments We thank Malaria Immunology Lab members for their valuable inputs. Quantitative assessment of multiorgan sequestration of parasites in fatal pediatric cerebral malaria. Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. Increased gastrointestinal permeability in patients with Plasmodium falciparum malaria. Malaria impairs resistance to Salmonella through hemeand heme oxygenaseÀdependent dysfunctional granulocyte mobilization. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Both hemolytic anemia and malaria parasite-specific factors increase susceptibility to Nontyphoidal Salmonella enterica serovar typhimurium infection in mice. Mast cells and histamine alter intestinal permeability during malaria parasite infection. Mucosal Immunol 2014;7(6): [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] 1302À11. Prolonged neutrophil dysfunction after Plasmodium falciparum malaria is related to hemolysis and heme oxygenase-1 induction. Lipocalin 2 bolsters innate and adaptive immune responses to blood-stage malaria infection by reinforcing host iron metabolism. Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen-the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1. Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. They obtain nutrients from the host and, in some cases, hitchhike from one host to another to develop into the next stage and complete their life cycle. Parasites are mainly classified into three groups: protozoans, helminths, and ectoparasites. Protozoans are unicellular organisms that live in the blood or tissue or inside cells in animals. Helminths are multicellular organisms with great diversity that can mostly be recognized by the naked eye. Parasitic helminths are further classified into trematodes (flukes), cestodes (tapeworms), and nematodes (roundworms). Ectoparasites parasitize on or in the skin of animals for the entire or part of their lives. Although one quarter of people in the world are estimated to be infected with helminths [1], many parasites are harmless when they parasitize the definitive hosts. In addition to prevention, the control of parasitic diseases has been carried out mainly by antiparasitic drugs that are cheap and effective against a wide spectrum of parasites. However, acquisition of drug resistance is a serious issue in various protozoan and helminth parasites [3]; therefore alternative ways to control parasitic diseases, such as vaccines, are needed. Although some vaccines against parasitic infections have been developed for poultry and other animals, no antiparasitic vaccine is available for human use [4,5]. An effective antiparasite host immune response is different depending on the parasite and is largely dependent on their habitat. Generally, cell-mediated immunity represented by type 1 T helper (Th1) cells is effective against intracellular protozoa [5,6]. On the other hand, Th2-mediated immune responses are important for exclusion of gastrointestinal helminths [7À10]. The main parasite infection routes are oral through contaminated water and food, and the skin by direct penetration or by arthropod transmission. A variety of parasites invade the gastrointestinal tract and/ or parasitize the gut and consequently interact with the mucosal immune system [5À10]. This article focuses on the recent advances in mucosal vaccines against parasitic diseases. Here, recent advances in the development of mucosal vaccines are discussed, with a focus on representative medically important protozoa that inhabit and/or invade through the gastrointestinal tract. Amoebiasis Amoebiasis that causes colitis, bloody diarrhea, and/or amoebic liver abscesses is a worldwide health problem. It is more common in tropical areas with poor sanitation conditions, with an estimated 40,000À74,000 deaths annually [11]. The etiological agent is Entamoeba histolytica, which is transmitted by the fecalÀoral route via contaminated water and food or by person-to-person contact [11].

The adjuvant activity is closely related to nanostructures psychological erectile dysfunction young cheap aczone 60 mg otc, since the mutation of key amino acid residues in the self-assembling domain demolishes the immunogenicity of the self-assembled peptide vaccines [48] impotence education cheap aczone express. The term "nanogel" defines refers to nanoscale particles ( benadryl causes erectile dysfunction buy generic aczone 30 mg,100 nm in diameter) composed of physically or chemically cross-linked bifunctional networks having good swelling capacity in aqueous environments [50] erectile dysfunction treatment wikipedia buy aczone 90 mg amex. Nanogels have a high cargo loading capacity erectile dysfunction doctor pune purchase 60 mg aczone mastercard, biocompatibility, and biodegradability. Cationic nanogels are adhesive to epithelial cell surface and serve as artificial chaperones protecting antigens from aggregation and denaturation. The surfaces of nanogels are relatively easy to modify by specific ligands, enabling targeted delivery to specific cells or tissues. Nanogel vaccine formulations can be delivered via a wide range of routes, such as parenteral, oral, nasal, pulmonary, or ocular administration [52]. Nanogels can be formulated by various polysaccharides such as chitosan, mannan, hyaluronic acid, dextrin, cycloamylose, pullulan, and enzymatically synthesized glucogen [53]. In recent years, pullulan has played a critical role in the development of nanogel systems for vaccine and drug delivery [54]. Pullulan is an aqueous polysaccharide synthesized by the yeast-like fungus Aureobasidium pullulans. Pullulan is widely used in diverse biomedical industries because it is easily modified by rather simple chemical reactions that are nontoxic, nonmutagenic, noncarcinogenic, and, most important, nonimmunogenic [55,56]. Pullulan hydrophobized by cholesterol becomes amphiphilic and forms self-aggregates [57]. In the nanomatrix, the nanogel protects denatured protein antigen as an artificial molecular chaperone and helps in proper refolding after release [61]. Epithelial cells served as a reservoir for the cargo antigen, while no overt cytotoxicity was observed. There have been continuous efforts to develop oral vaccines because of the advantages of oral vaccination. After the September 11, 2001, terrorist attacks, the threat of biological warfare became highlighted worldwide. Advantages and Limitations of Oral Vaccines Oral vaccination has several advantages, such as better patient compliance, mass immunization capability, easy administration or selfdelivery, simplified production and storage, lower production cost, and no needleassociated risks such as injuries and carryover infections (Table 19. The most important virtues of oral vaccination are its needle-free painless administration and that there is no need for trained personnel for administration. Two major mucosal vaccination routes, oral and intranasal, are compared in Table 19. The same concerns apply to other mucosal vaccines using live attenuated organisms. But generally, oral vaccines are regarded as a better choice than injectable parenteral vaccines from production, economic, and regulatory perspectives [70]. Oral vaccines are better for large-scale production and mass vaccination campaigns in developing countries, since no needles are required and self-administration is possible. Thermostabilization technologies would enable successful cold-chain-free vaccination of killed as well as live attenuated formulations in resourcepoor settings such as developing countries [71]. Many oral vaccines that proved to be efficacious in preclinical studies have failed in clinical trials. Oral vaccines should have strong immune-stimulatory adjuvants and optimal delivery strategies to drive effective innate and adaptive immune responses against vaccine antigens [64]. Vaccine antigen can be delivered inside the core or attached on the outside to the shell of micelles, depending on the electrochemical properties of the vaccine formulation [77]. The copolymers showed an innate adjuvant activity and caused no significant adverse reactions [78]. However, micelles may have a propensity to dissociate when diluted, leading to a loss of loaded antigen. Conventional liposomes are vulnerable to acidic gastric juice and are easily digested by pancreatic lipase [81]. Also, intestinal bile salts can destroy the phospholipid membrane integrity and lyse the liposomes, resulting in the premature release of vaccine antigens [82]. To tackle these problems, researchers have investigated different lipid moieties such as archaeal lipids or bile salts in the liposomal membrane [83,84]. Positively charged (cationic) liposomes have been demonstrated to possess the strongest adjuvanticity compared to neutral and negatively charged liposomes [85]. Cationic liposomes also better adhere to negatively charged membranes of M cells and enterocytes, limiting flushing by peristalsis and providing a better chance to be internalized [86]. Recently, a study reported that cationic liposomes induce necrosis to release damageassociated molecular patterns and cause inflammation in vivo [87]. The first, "classical" type was manufactured to entrap protein antigens, making them act as both a vaccine antigen delivery and an adjuvant system. These recent technologies enable overcoming previous barriers in oral vaccination and allow better targeting of antigens and adjuvants to the desired tissue location and cells. Particles can be engineered to release antigens and adjuvants upon degradation, swelling, and diffusion from the polymer, or change in electrostatic interactions. The production of particles in defined sizes, architectures, and chemical properties would enable oral delivery, which is the most difficult vaccination route in terms of targeted delivery, thanks to the major development in nanotechnology and biomaterial science. Depending upon the polymer choices, the delivery systems by themselves provide adjuvant activity along with biocompatibility and biodegradability. To be licensed and clinically used for mucosal vaccine delivery, nanocarriers should be able to protect the payload from degradation, to penetrate the mucus barriers, and to control the release of both antigens and adjuvants at targeted sites. In principle, these properties could be tuned by altering their particle size, surface chemistry, and three-dimensional architecture [79]. Despite some controversies, particles with a diameter smaller than 1 m are thought to have a better chance of being taken up by M cells [115]. Claudin 4, one a member of the integral membrane protein family expressed primarily in tight junctions, also serves as a target for developing M-cell-binding nanocarriers [128]. The mucoadhesive polymers prolong retention time of the particles in the mucus by steric or adhesive interactions. Conjugation of immunostimulatory ligands to bioadhesive polymers should induce longer-lasting mucosal and systemic immune responses against entrapped antigens. Modifications through quarterization, thiolation, acylation, and grafting resulted in copolymers with higher mucoadhesion strength, increased hydrophobic interactions (advantageous in hydrophobic antigen entrapment), and increased solubility in alkaline pH, higher solubility, and controlled/ extended release profiles, which consequently confer wider application of chitosan derivatives for oral vaccine delivery [140,141]. Chitosan and its derivatives are mucoadhesive and have the ability to stimulate immune cells either by directly interacting with the M cells or by opening the tight junctions between the epithelial cells [142]. Alginate has been used to make oral vaccine carriers utilizing its acid resistance and immunostimulatory properties [145]. Owing to its acid resistance property, alginate is also used to encapsulate bacterial cells to develop oral vaccines. Oral vaccines against Edwardsiella, Brucella, and Aeromonas infections were also developed by encapsulation with alginate [149À152]. Glucan microparticles target enterocytes and M cells for uptake and activate them to secrete and express cytokines and -glucan receptors [154À156]. One reason for the limited use of glucan particles is that their manufacture is currently limited to liquid formulations, which require cold-chain storage and therefore are not optimal for the use in poorer regions [79]. One more problem standing in the way of wider distribution of desperately needed vaccines is that the conventional cell fermentation systems for producing recombinant protein vaccine antigens are often expensive and are not easily scalable [160]. Another emerging infectious disease field is One Health, dealing with zoonotic diseases spreading in both animals and humans. Molecular farming has become well established for the production of vaccines, and many proofs of principle and important proofs of efficacy are accumulating continuously [161]. MucoRice should be one of the most innovative approaches for oral vaccine delivery using edible rice as a carrier (Chapter 20: Plant-Based Mucosal Vaccine Delivery Systems). Rice seeds have stability and resistance to digestion in the stomach, making MucoRice an attractive oral vaccine delivery system. These results show that the MucoRice vaccine could be stockpiled longer at room temperature and could be widely used for oral vaccination without cold-chain management. Tablets and Capsules the most widely used form of whole bacterial cell vaccines for cholera and typhoid fever was liquid suspension. Because of the lack of shelf stability, the liquid format is unsuitable for storage and distribution in developing countries. In this regard, a stable solid dosage vaccine platform is required for those vaccines. Formulation in tablets or capsules would provide more stability and ease of handling. Capsules could be manufactured in appropriate physical sizes (the average size of capsules and tablets ranges from 5 to 20 mm) suitable for administration to target populations. With enteric coatings, tablets and capsules could be protected from gastric acid and endowed with controlled release properties, which will provide facilitated delivery to discrete locations in the intestine. In principle, capsules allow the incorporation of many previously introduced delivery technologies in one primary delivery format. The Serum Institute of India licensed the monovalent NasoVac against pandemic A/California/7/2009 H1N1 influenza (Chapter 39: Nasal Influenza Vaccines). The human nasal cavity is an attractive route of mucosal immunization, having a total surface area of 150 cm2 with a volume of 15À20 mL [52,170,171]. The nasal cavity is divided into five anatomical and functional regions: the nasal vestibule, the atrium, the respiratory region, the olfactory region, and the nasopharynx [171]. The respiratory region is where nasal delivery of drugs and vaccines occurs, since it is the most permeable region, having a large surface area and a rich vascular bed [172]. The respiratory region is covered by a pseudostratified epithelium composed of columnar cells interspersed with goblet cells, which are interconnected by tight junctions (zonae occludens). The tight junctions are relatively resistant to paracellular passages of particulate materials in the breathed air [173]. The mucus layer in the nasal tract is relatively thinner (5 m) than other mucosal surfaces. The mucociliary clearance mechanism should have negative effects on nasal vaccination. The rapid turnover of mucus (10À15 minutes) and fast mucus flow (B5 mm/min) in the nasal cavity limit the length of residence of administered vaccine. Continuous outward movement of cilia on the epithelial apical surface accelerates the clearance of mucus-trapped substances. To make matters worse, nasal enzymes and local pH negatively affect the stability of nasally administered vaccine antigens [170]. A live influenza virus should be able to survive in the nasal mucosa and be harnessed with built-in adjuvants. An inactivated split influenza vaccine was also tested for nasal delivery but proved ineffective without coformulation with appropriate mucosal adjuvants [176À178]. To achieve equivalent antibody responses without adjuvant, an inactivated split antigen should be given at least three times more, or an inactivated whole virus should have been immunized [179À181]. Given that even an inactivated virus antigen requires potent mucosal adjuvants to achieve optimal immune responses in the systemic and mucosal compartments, protein antigens should employ even stronger mucosal adjuvants to be effective by nasal vaccination. Many mucosal adjuvants are suggested as formulation partners of nasal vaccine antigens [182,183]. The use of enterotoxins as nasal vaccine adjuvants has a very serious failure history. Since the nasal cavity and brain are separated by a thin anatomical structure and are directly connected by the olfactory nerve, binding of any vaccine component to the olfactory nerve should contribute neurotoxicity. In this context, any nasal vaccine, adjuvant, or delivery system must clear the safety concern to be introduced to the market. Vaccine antigens should remain sufficiently stable in the nasal mucosa and should be able to reach to antigen-capturing cells surviving the mucociliary clearance mechanism. To overcome those hurdles, micro/nanocarriers for nasal vaccine delivery have been actively researched. To increase the residence time at mucosal surfaces, several strategies have been developed to increase adhesiveness of antigen delivery systems to the nasal mucus [191,192]. However, the mucus is not a static barrier; it is continuously secreted and cleared from the nasal cavity by the cilia beating on columnar epithelial cells. Mucoadhesion ability of delivery carrier would cause earlier removal of vaccine antigens when mucociliary clearance mechanism is intact. Strategies that prevent vaccine carrierÀmucus interactions and hence allow for free diffusion by mucopenetration should be more effective in inducing efficacious immune responses [196]. Advantages and Limitations of Nasal Vaccines the comparative advantages and disadvantages of intranasal vaccination are summarized in Table 19. The most outstanding advantage is the ease of administration, while the safety issue is the most essential problem to be resolved. Despite the promising results of in vitro and animal studies, the application of nanoemulsions for nasal delivery in humans appears to be hindered mainly by the lack of detailed toxicology studies and the lack of extensive clinical trials [198]. A cationic nanoemulsion formulation could have facilitated cellular uptake of model antigen ovalbumin in the nasal epithelial cell line [199]. Induction of cell-mediated immunity is another important feature of liposomemediated adjuvanticity [204]. Chitosan solutions seem to induce balanced Th1 and Th2 responses with neutralizing antibodies [211]. Whole influenza virus formulated with trimethylated chitosan showed much closer interaction with the epithelial surface, with the potential to generate enhanced uptake and induction of immune responses with minimal local toxicity in terms of ciliary beat frequency in the nasal cavity [212]. Chitosan dry power in salt form enables a thermally stable vaccine formulation that does not require cold chains. Chitosan power formulations were shown to outperform solutions in eliciting humoral responses against diphtheria, anthrax, and norovirus [213]. Chitosan particles are basically mucoadhesive and able to deliver adjuvants and antigen cargos to efficiently promote humoral and cellular immune responses. To be used for better intranasal delivery, chitosan should be chemically modified for better solubility, stability, mucoadhesiveness, safety, and resilience against degradation [214]. Chitosan itself shows strong adhesion to mucosal surfaces, providing a longer retention time at the nasal mucosa, and disrupts the tight junctions between nasal epithelial cells, which leads to enhanced paracellular transport of antigens [167].

Based on your observations erectile dysfunction medication new 30 mg aczone buy visa, determine and record whether each organism was capable of fermenting glucose with ultimate production of acetylmethylcarbinol erectile dysfunction hernia order aczone 30 mg online. Differentiate between enteric organisms by their ability to ferment citrate as a sole source of carbon impotence remedies purchase aczone toronto. This ability depends on the presence of a citrate permease that facilitates the transport of citrate in the cell impotence at age 70 purchase aczone 90 mg with mastercard. Citrate is the first major intermediate in the Krebs cycle erectile dysfunction toys 90 mg aczone buy fast delivery, and is produced by the condensation of active acetyl with oxaloacetic acid. Citrate is acted on by the enzyme citrase, which produces oxaloacetic acid and acetate. These products are then enzymatically converted to pyruvic acid and carbon dioxide. During this reaction, the medium becomes alkaline-the carbon dioxide that is generated combines with sodium and water to form sodium carbonate, an alkaline product. The presence of sodium carbonate changes the bromthymol blue indicator incorporated into the medium from green to deep Prussian blue. Following incubation, citrate-positive cultures are identified by the presence of growth on the surface of the slant, which is accompanied by blue coloration, as seen with E. For the long version, 24- to 48-hour Trypticase soy broth cultures of the 13 organisms listed on page 152. Media Simmons citrate agar slants per designated student group 4 for the short version 14 for the long version Equipment Microincinerator or Bunsen burner Inoculating needle Test tube rack Glassware marking pencil Procedure Lab One 1. Examine all agar slant cultures for the presence or absence of growth and coloration of the medium. Based on your observations, determine and record whether each organism was capable of using citrate as its sole source of carbon. Account for the development of alkalinity in cultures capable of using citrate as their sole carbon source. Why do we test for the presence of indole rather than pyruvic acid as the indicator of tryptophanase activity Simmons citrate medium contains primarily inorganic ammonium, potassium, and sodium salts, plus organic citrate. What is the rationale for using a medium with this type of composition for the performance of the citrate utilization test Explain how microorganisms produce hydrogen sulfide from sulfur-containing amino acids or inorganic sulfur compounds. Pathway 1: Gaseous H2S may be produced by the reduction (hydrogenation) of organic sulfur present in the amino acid cysteine, which is a component of peptones contained in the medium. These peptones are degraded by microbial enzymes to amino acids, including the sulfurcontaining amino acid cysteine. Regardless of which pathway is used, the hydrogen sulfide gas is colorless and therefore not visible. Ferrous ammonium sulfate in the medium serves as an indicator by combining with the gas, forming an insoluble black ferrous sulfide precipitate that is seen along the line of the stab inoculation and is indicative of H2S production. The medium contains sodium thiosulfate, which certain microorganisms are capable of reducing to sulfite with the liberation of hydrogen sulfide. Motility is recognized when culture growth (turbidity) of flagellated organisms is not restricted to the line of inoculation. Aseptically inoculate each experimental organism into its appropriately labeled tube by means of stab inoculation. Based on your observations, determine and record whether each organism was capable of producing hydrogen sulfide. Bacteria belonging to the genera Salmonella and Proteus enzymatically metabolize inorganic sulfur compounds and sulfur-containing amino acids, producing H2S. The hydrogen sulfide test is one way to separate and identify Shigella dysentariae, which does not produce H2S, from Proteus and Salmonella. Distinguish between the types of substrates available to cells for H2S production. A stool specimen of a patient with severe diarrhea was cultured in a series of specialized media for isolation of enteric organisms. The cultures yielded three isolates that were species of Salmonella, Shigella, and Escherichia. Although other organisms may produce urease, their action on the substrate urea tends to be slower than that seen with Proteus species. Therefore, this test serves to rapidly distinguish members of this genus from other non­lactose-fermenting enteric microorganisms. Urease is a hydrolytic enzyme that attacks the nitrogen­carbon bond in amide compounds such as urea and forms the alkaline end product ammonia. The presence of urease is detectable when the organisms are grown in a urea broth medium containing the pH indicator phenol red. As the substrate urea is split into its products, the presence of ammonia creates an alkaline environment that causes the phenol red to turn to a deep pink. Many enterics can degrade urea, but only a few are termed rapid urease-positive organisms. While part of the normal flora, these commensals have been identified as opportunistic pathogens. Members of the gastroduodenal commensals are included among this group of organisms. Using aseptic technique, inoculate each experimental organism into its appropriately labeled tube by means of loop inoculation. Based on your observations, determine and record whether each organism was capable of hydrolyzing the substrate urea. Explain how the urease test is useful for identifying members of the genus Proteus. A swollen can of chicken soup is examined by the public health laboratory and found to contain large numbers of gram-negative, H2S-positive bacilli. Which biochemical tests would you perform to identify the genus of the contaminant Differentiate between microorganisms that enzymatically transform different milk substrates into varied metabolic end products. The presence of lactic acid is easily detected because litmus is purple at a neutral pH and turns pink when the medium is acidified to an approximate pH of 4. The presence of gas may be seen in separations of the curd or by the development of tracks or fissures within the curd as gas rises to the surface. Principle the major milk substrates capable of transformation are the milk sugar lactose and the milk proteins casein, lactalbumin, and lactoglobulin. To distinguish among the metabolic changes produced in milk, a pH indicator, the oxidationreduction indicator litmus, is incorporated into the medium. Litmus milk now forms an excellent differential medium in which microorganisms can metabolize milk substrates depending on their enzymatic complement. A variety of different biochemical changes result, as follows: Lactose fermentation Gas production Litmus reduction Curd formation Proteolysis Alkaline reaction Litmus Reduction Fermentation is an anaerobic process involving biooxidations that occur in the absence of molecular oxygen. These oxidations may be visualized as the removal of hydrogen (dehydrogenation) from a substrate. Since hydrogen ions cannot exist in the free state, there must be an immediate and concomitant electron acceptor available to bind these hydrogen ions, or else oxidation-reduction reactions are not possible and cells cannot manufacture energy. While in the oxidized state, the litmus is purple; when it accepts hydrogen from a substrate, it will become reduced and turn white or milkcolored. Lactic acid 193 Curd Formation the biochemical activities of different microorganisms grown in litmus milk may result in the production of two distinct types of curds (clots). Curds are designated as either acid or rennet, depending on the biochemical mechanism responsible for their formation. Acid curd Lactic acid or other organic acids cause precipitation of the milk protein casein as calcium caseinate to form an insoluble clot. An acid curd is easily identified if the tube is inverted and the clot remains immoble. Some organisms produce rennin, an enzyme that acts on casein to form paracasein, which in the presence of calcium ions is converted to calcium paracaseinate and forms an insoluble clot. Unlike the acid curd, this is a soft semisolid clot that will flow slowly when the tube is tilted. Curd Rennet curd the partial degradation of casein into shorter polypeptide chains, with the simultaneous release of alkaline end products that are responsible for the observable color change. This digestion of proteins is accompanied by the evolution of large quantities of ammonia, resulting in an alkaline pH in the medium. The litmus turns deep purple in the upper portion of the tube, while the medium begins to lose body and produces a translucent, brown, whey-like appearance as the protein is hydrolyzed to amino acids. Alkaline Reaction An alkaline reaction is evident when the color of the medium remains unchanged or changes to a deeper blue. Using aseptic technique, inoculate each experimental organism into its appropriately labeled tube by means of a loop inoculation. Based on your observations, determine and record the type(s) of reaction(s) that have taken place in each culture. Describe the litmus milk reactions that may occur when proteins are metabolized as an energy source. Can a litmus milk culture show a pink band at the top and a brownish translucent layer at the bottom Principle the reduction of nitrates by some aerobic and facultative anaerobic microorganisms occurs in the absence of molecular oxygen, an anaerobic process. The semisolidity impedes the diffusion of oxygen into the medium, thereby favoring the anaerobic requirement for nitrate reduction. Following reduction, the addition of Solutions A and B will produce an immediate cherry red color. To determine whether nitrates were reduced past the nitrite stage, a small amount of zinc powder is added to the basically colorless cultures already containing Solutions A and B. The development of red color therefore verifies that nitrates were not reduced to nitrites by the organism. If the addition of zinc does not produce a color change, the nitrates in the medium were reduced beyond nitrites to ammonia or nitrogen gas. When presented with a patient who exhibits the symptoms of tuberculosis and is positive for tubercles on an x-ray, test a sputum sample for Mycobacterium. To distinguish between Mycobacterium tuberculosis and other Mycobacterium species, a nitrate reduction test is used, since M. Add five drops of Solution A and then five drops of Solution B to all nitrate broth cultures. Observe and record in the Lab Report chart whether a red coloration develops in each of the cultures. On the basis of your observations, determine and record in the Lab Report chart whether each organism was capable of nitrate reduction. If a culture did not undergo a color change on the addition of Solutions A and B, explain how you would interpret this result. Explain why the development of a red color on the addition of zinc is a negative test. Determine how some microorganisms degrade hydrogen peroxide by producing the enzyme catalase. This is a positive catalase test; the absence of bubble formation is a negative catalase test. Accumulation of these substances will result in death of the organism unless they can be enzymatically degraded. These substances are produced when aerobes, facultative anaerobes, and microaerophiles use the aerobic respiratory pathway, in which oxygen is the final electron acceptor, during degradation of carbohydrates for energy production. With the increasing worry about methicillin-resistant strains of Staphylococcus in hospitals, the catalase test is a quick and easy way to differentiate S. The inability of strict anaerobes to synthesize catalase, peroxidase, or superoxide dismutase may explain why oxygen is poisonous to these microorganisms. In the absence of these enzymes, the toxic concentration of H2O2 cannot be degraded when these organisms are cultivated in the presence of oxygen. Catalase production can be determined by adding the substrate H2O2 to an appropriately incubated Trypticase soy agar slant culture. Negative results are shown on the left and positive results on the right in the (a) tube method and (b) plate method. Negative results are shown on the top and positive results on the bottom in the (c) slide method. Allow three or four drops of the 3% hydrogen peroxide to flow over the entire surface of each slant culture. Based on your observations, determine and record whether each organism was capable of catalase activity. Reagent 3% hydrogen peroxide Equipment Microincinerator or Bunsen burner Inoculating loop Test tube rack Glassware marking pencil Glass microscope slides Petri dish and cover Slide Method 1. Using a sterile loop, collect a small sample of the first organism from the culture tube and transfer it to the appropriately labeled slide. Using aseptic technique, inoculate each experimental organism into its appropriately labeled tube by means of a streak inoculation. Illustrate the chemical reaction involved in the degradation of hydrogen peroxide in the presence of catalase. Account for the ability of streptococci to tolerate O2 in the absence of catalase activity.

Aczone 30 mg order visa. Rapport Classic - English with Bahasa Indonesia Subtitles.

References